Size exclusion chromatography as a characterization tool for quality control of marine biopharmaceutical keyhole limpet hemocyanin
References
- W.-H. Boehncke and N. C. Brembilla, Immunogenicity of biologic therapies: Causes and consequences, Expert Rev. Clin. Immunol. 14 (2018) 513–523; https://doi.org/10.1080/1744666X.2018.1468753
- Biologic Therapeutic Drugs: Technologies and Global Markets, BCC Research, May 2025; https://www.giiresearch.com/report/bc1735431-biologic-therapeutic-drugs-technologies-global.html; last access date January 22, 2026.
- A. Mullard, 2025 FDA approvals, Nat. Rev. Drug Discov. January 2026; https://doi.org/10.1038/d41573-026-00001-z
- M. Kesik-Brodacka, Progress in biopharmaceutical development, Biotechnol. Appl. Biochem. 65 (2018) 306–322; https://doi.org/10.1002/bab.1617
- A. V. Maksimenko, Development and application of targeted therapeutic protein conjugates, Russ. J. Gen. Chem. 84 (2014) 357–363; https://doi.org/10.1134/S1070363214020376
- K. Fosgerau and T. Hoffmann, Peptide therapeutics: Current status and future directions, Drug Discov. Today 20 (2015) 122–128; https://doi.org/10.1016/j.drudis.2014.10.003
- L. Wang, N. Wang, W. Zhang, X. Cheng, Z. Yan, G. Shao, X. Wang, R. Wang and C. Fu, Therapeutic peptides: Current applications and future directions, Signal Transduct. Target. Ther. 7 (2022) Article ID 48 (27 pages); https://doi.org/10.1038/s41392-022-00904-4
- D. A. Díaz-Dinamarca, M. L. Salazar, B. N. Castillo, A. Manubens, A. E. Vasquez, F. Salazar and M. I. Becker, Protein-based adjuvants for vaccines as immunomodulators of the innate and adaptive immune response: Current knowledge, challenges, and future opportunities, Pharmaceutics 14(8) (2022) Article ID 1671 (23 pages); https://doi.org/10.3390/pharmaceutics14081671
- M. L. Salazar, D. A. Díaz-Dinamarca, J. Bustamante, F. Vergara, A. Manubens, F. Salazar and M. I. Becker, Hemocyanins: Microscopic giants with unique structural features for applications in biomedicine, Vaccines 13 (2025) Article ID 1086 (38 pages); https://doi.org/10.3390/vaccines13111086
- S. Liu, M. Yang, B. Xi, Y. Wang, A. Zhang, A. Liu and H. Jin, Paediatric solid tumour vaccines: Current processes, prevailing challenges and future perspectives, Immunology 178 (2026) 38–61; https://doi.org/10.1111/imm.70105
- S. Kelliny, X.-F. Zhou and L. Bobrovskaya, Alzheimer’s Disease and frontotemporal dementia: A review of pathophysiology and therapeutic approaches, J. Neurosci. Res. 103 (2025) e70046 (43 pages); https://doi.org/10.1002/jnr.70046
- X.-Y. Zhang, Y. Meng, X.-J. Yan, S. Liu, G.-Q. Wang and Y.-P. Cao, Immunization with Aβ3-10-KLH vaccine improves cognitive function and ameliorates mitochondrial dysfunction and reduces Alzheimer’s disease-like pathology in Tg-APPswe/PSEN1dE9 mice, Brain Res. Bull. 174 (2021) 31–40; https://doi.org/10.1016/j.brainresbull.2021.05.019
- P. Novak, N. Zilka, M. Zilkova, B. Kovacech, R. Skrabana, M. Ondrus, L. Fialova, E. Kontsekova, M. Otto and M. Novak, AADvac1, an active immunotherapy for Alzheimer’s disease and non Alzheimer tauopathies: An overview of preclinical and clinical development, J. Prev. Alzheimer’s Dis. 6 (2019) 63–69; https://doi.org/10.14283/jpad.2018.45
- M. D. Raleigh, M. Laudenbach, F. Baruffaldi, S. J. Peterson, M. J. Roslawski, A. K. Birnbaum, F. I. Carroll, S. P. Runyon, S. Winston, P. R. Pentel and M. Pravetoni, Opioid dose- and route-dependent efficacy of oxycodone and heroin vaccines in rats, J. Pharmacol. Exp. Ther. 365 (2018) 346–353; https://doi.org/10.1124/jpet.117.247049
- T. Lu, X. Li, W. Zheng, C. Kuang, B. Wu, X. Liu, Y. Xue, J. Shi, L. Lu and Y. Han, Vaccines to treat substance use disorders: Current status and future directions, Pharmaceutics 16 (2024) Article ID 84 (17 pages); https://doi.org/10.3390/pharmaceutics16010084
- S. Kato, T. Matsui, C. Gatsogiannis and Y. Tanaka, Molluscan hemocyanin: structure, evolution, and physiology, Biophys. Rev. 10 (2018) 191–202; https://doi.org/10.1007/s12551-017-0349-4
- P. Cermakova, O. Cehlar and J. Piestansky, Unlocking the potency of keyhole limpet hemocyanin: Structural insights, immunological mechanisms, and therapeutic frontiers, Int. J. Mol. Sci. 27 (2026) Article ID 7921 (30 pages); https://doi.org/10.1016/j.jpba.2016.05.028
- M. K. Parr, O. Montacir and H. Montacir, Physicochemical characterization of biopharmaceuticals, J. Pharm. Biomed. Anal. (Review Issue 2016) 130 (2016) 366–389; https://doi.org/10.1016/j.jpba.2016.05.028
- S. A. Berkowitz, J. R. Engen, J. R. Mazzeo and G. B. Jones, Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars, Nat. Rev. Drug Discov. 11 (2012) 527–540; https://doi.org/10.1038/nrd3746
- V. K. Sharma and D. S. Kalonia, Experimental Detection and Characterization of Protein Aggregates, in Aggregation of Therapeutic Proteins (Eds. W. Wang and C. J. Roberts), 1st ed., John Wiley & Sons, Ltd, 2010 Hoboken (NJ) USA, Chapter 5 (pp. 205–256); https://doi.org/10.1002/9780470769829.ch5
- E. M. Moussa, J. P. Panchal, B. S. Moorthy, J. S. Blum, M. K. Joubert, L. O. Narhi and E. M. Topp, Immunogenicity of therapeutic protein aggregates, J. Pharm. Sci. 105 (2016) 417–430; https://doi.org/10.1016/j.xphs.2015.11.002
- K. D. Ratanji, J. P. Derrick, R. J. Dearman and I. Kimber, Immunogenicity of therapeutic proteins: Influence of aggregation, J. Immunotoxicol. 11 (2014) 99–109; https://doi.org/10.3109/1547691X.2013.821564
- C. J. Roberts, Therapeutic protein aggregation: mechanisms, design, and control, Trends Biotechnol. 32 (2014) 372–380; https://doi.org/10.1016/j.tibtech.2014.05.005
- K. D. Ratanji, R. J. Dearman, I. Kimber, R. Thorpe, M. Wadhwa and J. P. Derrick, Editor’s Highlight: Subvisible aggregates of immunogenic proteins promote a Th1-type response, Toxicol. Sci. 153 (2016) 258–270; https://doi.org/10.1093/toxsci/kfw121
- N. Chakroun, D. Hilton, S. S. Ahmad, G. W. Platt and P. A. Dalby, Mapping the aggregation kinetics of a therapeutic antibody fragment, Mol. Pharm. 13 (2016) 307–319; https://doi.org/10.1021/acs.molpharmaceut.5b00387
- M. Haberger, M. Leiss, A.-K. Heidenreich, O. Pester, G. Hafenmair, M. Hook, L. Bonnington, H. Wegele, M. Haindl, D. Reusch and P. Bulau, Rapid characterization of biotherapeutic proteins by size-exclusion chromatography coupled to native mass spectrometry, mAbs 8 (2016) 331–339; https://doi.org/10.1080/19420862.2015.1122150
- S. Fekete, A. Beck, J.-L. Veuthey and D. Guillarme, Theory and practice of size exclusion chromatography for the analysis of protein aggregates, J. Pharm. Biomed. Anal. (Reviews 2014) 101 (2014) 161–173; https://doi.org/10.1016/j.jpba.2014.04.011
- S. Fekete, L. Kizekai, Y. T. Sarisozen, N. Lawrence, S. Shiner and M. Lauber, Investigating the secondary interactions of packing materials for size-exclusion chromatography of therapeutic proteins, J. Chromatogr. A 1676 (2022) Article ID 463262 (10 pages); https://doi.org/10.1002/jssc.201700988
- S. Fekete and M. Lauber, Insights on further improving fast size exclusion chromatography separations of biopharmaceuticals using 2.1 millimetre column diameters, J. Chromatogr. A 1690 (2023) Article ID 463810 (7 pages); https://doi.org/10.1016/j.chroma.2023.463810
- M. Imiolek, S. Fekete, L. Kizekai, B. Addepalli and M. Lauber, Fast and efficient size exclusion chromatography of adeno associated viral vectors with 2.5 micrometer particle low adsorption columns, J. Chromatogr. A 1714 (2024) Article ID 464587 (10 pages); https://doi.org/10.1016/j.chroma.2023.464587
- S. Fekete, M. Lauber and M. Xu, Considering the selectivity of pore size gradient size exclusion chromatography columns, J. Chromatogr. A 1718 (2024) Article ID 464726 (11 pages); https://doi.org/10.1016/j.chroma.2024.464726
- S. Fekete and M. Imiolek, Quantitative description of the quality of size exclusion chromatography separations, J. Chromatogr. A 1730 (2024) Article ID 465051 (8 pages); https://doi.org/10.1016/j.chroma.2024.465051
- F. Gritti and S. Fekete, Band broadening in pore size gradient size exclusion chromatography columns, J. Chromatogr. A 1765 (2026) Article ID 466523 (8 pages); https://doi.org/10.1016/j.chroma.2025.466523
- M. Buff, A. Goyon, K. Zhang and D. Guillarme, Benchmarking size-exclusion chromatography columns for the analysis of therapeutic peptides and model oligonucleotides, J. Chromatogr. A 1775 (2026) Article ID 466909 (14 pages); https://doi.org/10.1016/j.chroma.2026.466909
- S. Fekete, M. Imiolek, M. Lauber, S. Ji, O. D. Tchoul and M. Xu, Comprehensive analysis of pore properties of ultra-wide pore size exclusion chromatography packing materials, J. Pharm. Biomed. Anal. 270 (2026) Article ID 117280 (12 pages); https://doi.org/10.1016/j.jpba.2025.117280
- S. Fekete, M. DeLano, A. B. Harrison, S. J. Shiner, J. L. Belanger, K. D. Wyndham and M. Lauber, Size exclusion and ion exchange chromatographic hardware modified with a hydrophilic hybrid surface, Anal. Chem. 94(7) (2022) 3360–3367; https://doi.org/10.1021/acs.analchem.1c05466
- V. D’Atri, M. Imiołek, C. Quinn, A. Finny, M. Lauber, S. Fekete and D. Guillarme, Size exclusion chromatography of biopharmaceutical products: From current practices for proteins to emerging trends for viral vectors, nucleic acids and lipid nanoparticles, J. Chromatogr. A 1722 (2024) Article ID 464862 (26 pages); https://doi.org/10.1016/j.chroma.2024.464862
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures Q2(R2), Final version, November 2023; https://database.ich.org/sites/default/files/ICH_Q2%28R2%29_Guideline_2023_1130_ErrorCorrection_2025.pdf; last access date June 28, 2026
Language: English
Accepted on: Sep 27, 2026
Published on: Oct 23, 2026
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2026 Paula Cermakova, Petra Majerova, Andrej Kovac, Juraj Piestansky, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.